|
Summary
October 2007, Vol. 11, No. 10, Pages 1339-1353
, DOI 10.1517/14728222.11.10.1339
c-Jun N-terminal kinases as potential therapeutic targetsBaljinder Salh1Associate Professor, University of British Columbia, Department of Medicine, Vancouver, BC, Canada 2Jack Bell Research Center, 2660 Oak Street, Vancouver, BC, V6H 3Z6, Canada 3Division of Gastroenterology, 5153-2775 Laurel Street, Vancouver, BC, V5Z 1M9, Canada + 1 604 875 5287; + 1 604 875 5447; bsalh@interchange.ubc.ca One principal aim of research in the signal transduction field is to identify targets for therapeutic intervention, in an attempt to modify disease and curtail human suffering. Diseases such as chronic inflammation, atherosclerosis, diabetes and cancer exact a huge toll on health, in physical, social and financial terms. Defective signaling mechanisms are central to their pathogenesis. One candidate signaling molecule that is presently undergoing intense investigation is the c-Jun N-terminal kinase. With roles described in almost all classes of disease, the main questions are what type of inhibitor to use and when exactly to use it during the disease course? Forward Links to Citing ArticlesInki Kim, Wenjie Xu, John C. Reed. (2009) Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nature Reviews Drug Discovery 7:12, 1013-1030 Online publication date: 1-Jan-2009. CrossRef Kosmas I. Paraskevas, Dimitri P. Mikhailidis. (2008) C-reactive protein (CRP): more than just an innocent bystander?. Current Medical Research and Opinion 24:1, 75-78 Online publication date: 1-Jan-2008. Summary | PDF (273 KB) | PDF Plus (273 KB) |
|





TOC Alert